ArticlePloS one2012
Protein signature of lung cancer tissues.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 90 citations in OpenAlex.
- Dissecting non-small cell lung cancer (NSCLC) with blood proteomics-from surgical to immunotherapeutic responses.NPJ precision oncology · 2026Article
- The Role of Low CD36 Expression in the Development of Non-Small Cell Lung Cancer and Its Potential for Therapy.Cancers · 2026Review
- The application of Aptamer in biomarker discovery.Biomarker research · 2023Review
- Application of Multiple Omics to Understand Postoperative Delirium Pathophysiology in Humans.Gerontology · 2023Review
- Speciation Analysis Highlights the Interactions of Auranofin with the Cytoskeleton Proteins of Lung Cancer Cells.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Serum Protein Signatures Using Aptamer-Based Proteomics for Minimal Change Disease and Membranous Nephropathy.Kidney international reports · 2022Article
- Slow Off-Rate Modified Aptamer (SOMAmer) Proteomic Analysis of Patient-Derived Malignant Glioma Identifies Distinct Cellular Proteomes.International journal of molecular sciences · 2021Article
- Comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities.Nature communications · 2020Article
- Airway Microbiota as a Modulator of Lung Cancer.International journal of molecular sciences · 2020Review
- Blood proteome profiling using aptamer-based technology for rejection biomarker discovery in transplantation.Scientific data · 2019Article
- Undulating changes in human plasma proteome profiles across the lifespan.Nature medicine · 2019Article
- The Role of Inflammation after Surgery for Elders (RISE) study: Study design, procedures, and cohort profile.Alzheimer's & dementia (Amsterdam, Netherlands) · 2019Article
- Application of Proteomics Profiling for Biomarker Discovery in Hypertrophic Cardiomyopathy.Journal of cardiovascular translational research · 2019Article
- Aptamer Profiling of A549 Cells Infected with Low-Pathogenicity and High-Pathogenicity Influenza Viruses.Viruses · 2019Article
- The imbalance in the complement system and its possible physiological mechanisms in patients with lung cancer.BMC cancer · 2019Article
- Bioinformatics analysis of microarray data to identify the candidate biomarkers of lung adenocarcinoma.PeerJ · 2019Article
- Proteomics: Clinical and research applications in respiratory diseases.Respirology (Carlton, Vic.) · 2018Review
- Increased levels of circulating MMP3 correlate with severe rejection in face transplantation.Scientific reports · 2018Article
- Classification of prostate cancer using a protease activity nanosensor library.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Aptamer-Based Proteomics Identifies Mortality-Associated Serum Biomarkers in Dialysis-Dependent AKI Patients.Kidney international reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains the most common cause of cancer-related mortality. We applied a highly multiplexed proteomic technology (SOMAscan) to compare protein expression signatures of non small-cell lung cancer (NSCLC) tissues with healthy adjacent and distant tissues from surgical resections. In this first report of SOMAscan applied to tissues, we highlight 36 proteins that exhibit the largest expression differences between matched tumor and non-tumor tissues. The concentrations of twenty proteins increased and sixteen decreased in tumor tissue, thirteen of which are novel for NSCLC. NSCLC tissue biomarkers identified here overlap with a core set identified in a large serum-based NSCLC study with SOMAscan. We show that large-scale comparative analysis of protein expression can be used to develop novel histochemical probes. As expected, relative differences in protein expression are greater in tissues than in serum. The combined results from tissue and serum present the most extensive view to date of the complex changes in NSCLC protein expression and provide important implications for diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.